Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | The evolving role of surgery in melanoma from de-escalation to escalation

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, discusses the evolving role of surgery in melanoma. De-escalation strategies in early melanoma have the potential to reduce wide local excisions and sentinel node involvement, while simultaneously examining the expanding role of surgery in stage four disease. Advances in vaccine studies and neoadjuvant treatments have enabled patients to live longer and develop local complications amenable to surgical intervention, reflecting a paradigm where both escalation and de-escalation approaches are now considered simultaneously in melanoma care. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yes, I mean, the role of surgery is rapidly changing. So here at the ESSO conference, we have been discussing the role of de-escalation in early melanoma, especially wide local excisions and if there is a need for central nodes in the future. Potentially, so that is one path we’re discussing and driving. The other path is what is the role of surgery in stage four disease. And that is increasing...

Yes, I mean, the role of surgery is rapidly changing. So here at the ESSO conference, we have been discussing the role of de-escalation in early melanoma, especially wide local excisions and if there is a need for central nodes in the future. Potentially, so that is one path we’re discussing and driving. The other path is what is the role of surgery in stage four disease. And that is increasing. And since we are in Madrid and ESMO was here last week, we have the new vaccine studies, more neoadjuvant treatments, but also more patients that live longer, but actually develop both local problems that can be solved with surgery. And we see an increase in it. So I think in melanoma now, we discuss both of these two things simultaneously, both escalation and de-escalation.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.